Investor

The rounds this investor is named on, who it invests beside, and where it shows up.

Typewriter Therapeutics[ PART ]

A biotech developing re-dosable, all-RNA gene-insertion therapies, including in vivo CAR T, for cancer, autoimmune and severe genetic diseases

Series A$56M2026-09-029

Company	Round	Amount	Announced	Role
Typewriter Therapeutics A biotech developing re-dosable, all-RNA gene-insertion therapies, including in vivo CAR T, for cancer, autoimmune and severe genetic diseases	Series A Verified against 4 of 9 sources	$56M	2026-09-02	[ PART ]